Education
About Us
Working with TipRanks
Follow Us
Athira Pharma (ATHA)
NASDAQ:ATHA
ATHA Stock Chart & Stats
$3.74
-$0.02(-3.33%)
At close: 4:00 PM EST
$3.74
-$0.02(-3.33%)
Day’s Range― - ―
52-Week Range$2.19 - $8.26
Previous CloseN/A
Volume52.95K
Average Volume (3M)37.98K
Market Cap
$14.99M
Enterprise Value-$17.00M
Total Cash (Recent Filing)$29.82M
Total Debt (Recent Filing)$1.02M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Nov 06, 2025EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.80
Shares Outstanding3,943,933
10 Day Avg. Volume33,972
30 Day Avg. Volume37,985
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.50
Price to Sales (P/S)0.00
P/FCF Ratio-0.23
Enterprise Value/Market Cap-1.13
Enterprise Value/Revenue-17.56
Enterprise Value/Gross Profit84.16
Enterprise Value/Ebitda0.30
Forecast
1Y Price Target
$4.00Price Target Upside6.95% Upside
Rating ConsensusHold
Number of Analyst Covering1
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentATH-1105 has demonstrated a favorable safety profile and was well-tolerated in a Phase 1 study, supporting continued clinical development.
Financial StabilityThere is now sufficient cash runway to support operations through the data readout following the company's restructuring and downsizing.
Regulatory EnvironmentThe development pathway for ALS is attractive due to the FDA's flexibility and recent accelerated approval of Tofersen using Nf-L as a surrogate biomarker.
Bears Say
Financial ChallengesGiven the discontinuation of fosgonimeton, ATHA has significantly restructured and reduced future operating expenses, indicating financial challenges.
Partnership ChallengesThe company is unlikely to advance the program without a partner, and a partnership is unlikely to materialize due to the challenging ALS space and negative data for prior lead asset.
Strategic UncertaintyA strategic transaction for ATHA could ultimately result, but visibility on when and with whom is low, leading analysts to recommend looking elsewhere for growth opportunities.
Athira Pharma News
ATHA FAQ
What was Athira Pharma’s price range in the past 12 months?
Athira Pharma lowest stock price was $2.19 and its highest was $8.26 in the past 12 months.
What is Athira Pharma’s market cap?
Athira Pharma’s market cap is $14.99M.
When is Athira Pharma’s upcoming earnings report date?
Athira Pharma’s upcoming earnings report date is Nov 06, 2025 which is in 22 days.
How were Athira Pharma’s earnings last quarter?
Athira Pharma released its earnings results on Aug 07, 2025. The company reported -$1.8 earnings per share for the quarter, missing the consensus estimate of -$1.533 by -$0.267.
Is Athira Pharma overvalued?
According to Wall Street analysts Athira Pharma’s price is currently Undervalued.
Does Athira Pharma pay dividends?
Athira Pharma does not currently pay dividends.
What is Athira Pharma’s EPS estimate?
Athira Pharma’s EPS estimate is -1.06.
How many shares outstanding does Athira Pharma have?
Athira Pharma has 3,943,933 shares outstanding.
What happened to Athira Pharma’s price movement after its last earnings report?
Athira Pharma reported an EPS of -$1.8 in its last earnings report, missing expectations of -$1.533. Following the earnings report the stock price went up 5.946%.
Which hedge fund is a major shareholder of Athira Pharma?
Currently, no hedge funds are holding shares in ATHA
Athira Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (6.95% Upside)
$4.00 (6.95% Upside)
Hedge Fund Trend
Increased
By 1.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.11%
12-Months-Change
Fundamentals
Return on Equity
-103.80%
Trailing 12-Months
Asset Growth
-68.05%
Trailing 12-Months
Company Description
Athira Pharma
Athira Pharma, Inc. (ATHA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The company is engaged in the research and development of small molecules that aim to restore neuronal health and function. Athira's lead therapeutic candidate, fosgonimeton, is designed to enhance the activity of the HGF/MET neurotrophic system, which plays a critical role in brain health and recovery.
ATHA Stock 12 Month Forecast
Average Price Target
$4.00
▲(6.95% Upside)
Technical Analysis
Citius Pharmaceuticals
―
Hookipa Pharma
―
NextCure
―
TransCode Therapeutics
―
HCW Biologics
―
Ownership Overview
10.60% Insiders
4.56% Mutual Funds
32.03% Other Institutional Investors
45.57% Public Companies and
Individual Investors